This guideline was developed by a multidisciplinary working group convened by NBOCC*
|Dr Neil Wetzig||Surgeon (chair)|
|Mr James Kollias||Surgeon|
|Dr Nirmala Pathmanathan||Pathologist|
|Dr Sue Pendlebury||Radiation Oncologist|
|Ms Leanne Pentland||Consumer Representative|
|Ms Sue Rovelli||Breast Care Nurse|
|Clinical Professor Roger Uren||Nuclear Medicine Physician|
The development of this guideline was overseen by a multidisciplinary working group convened by NBOCC*: Dr Karen Luxford (Facilitator), Associate Professor Michael Bilous, Ms Elizabeth Kochman, Mr James Kollias, Dr Craig Lewis, Dr Jonathon Osborne, Dr Sue Pendlebury, Ms Leanne Pentland, Associate Professor Kelly-Anne Phillips, Ms Sue Rovelli, Dr Jane Turner
|Ms Heidi Wilcoxon||Senior Project Officer (Project lead)|
|Ms Katrina Anderson||Project OfficeróResearch|
|Dr Karen Luxford||General Manager|
|Ms Alison Pearce||Program Manager|
|Ms Rosemary Vagg||Senior Project OfficeróResearch|
|Dr Helen Zorbas||Director|
NBOCC* acknowledges those who gave their time to provide comment on the draft guideline recommendations as part of the external review process.
Full details of trial results are provided in the document Sentinel node biopsy for early breast cancer; a systematic review 2007†which can be accessed via the NBOCC* website www.nbocc.org.au
Priority topic areas for NBOCC* guideline development are determined in consultation with key stakeholders including experts in relevant disciplines and consumer representatives. A specific multidisciplinary Working Group, including consumers, is established for each topic identified and is involved in all aspects of guideline development. A systematic evidence review is undertaken for each guideline. All members are asked to declare any conflicts of interest and these declarations are recorded.† The content of the guideline is not influenced by any external funding body. The guideline is reviewed externally by key stakeholders and the wider community and endorsement is sought from relevant professional colleges and groups in Australia.
Recommendations for use of sentinel node biopsy in early (operable) breast cancer was prepared and produced by:
National Breast and Ovarian Cancer Centre*
Level 1, Suite 103, 355 Crown Street Surry Hills NSW 2010
Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 Frecall 1800 624 973
© Cancer Australia 2011
ISBN Print: 978-1-74127-112-6 Online: 978-1-74127-113-3 CI P: 618.190758
This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from National Breast and Ovarian Cancer Centre*. Requests and enquiries concerning reproduction and rights should be addressed to Corporate Communications Manager, National Breast and Ovarian Cancer Centre*
National Breast and Ovarian Cancer Centre*. Recommendations for use of sentinel node biopsy in early (operable) breast cancer. National Breast and Ovarian Cancer Centre*, Surry Hills, NSW, 2010.
National Breast and Ovarian Cancer Centre* does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. National Breast and Ovarian Cancer Centre* develops material based on the best available evidence, however it cannot guarantee and assumes no legal liability or responsibility for the currency or completeness of the information.
National Breast and Ovarian Cancer Centre* is funded by the Australian Government Department of Health and Ageing.
* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.